- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06799481
Virtuele thuisgebaseerde trainingsinterventie (stijging) om kankergerelateerde cognitieve stoornissen en darmmicrobioom te verbeteren bij overlevenden van adolescente en jonge volwassen hersentumor
Vrijwel geleverde thuisgebaseerde oefeninterventie op cognitieve stoornissen en darmmicrobioom bij overlevenden van adolescenten en jonge volwassen hersentumor: een piloot gerandomiseerde gecontroleerde studie
This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors. This clinical trial also evaluates the impact of RISE on the collection of microorganisms that exist in the intestines (gut microbiome). Up to 45% of AYA brain tumor survivors experience CRCI, including issues with attention and memory. CRCI can have a negative impact on education, independent living and can worsen long-term quality of life. Moderate-intensity levels of exercise, particularly aerobic and resistance training, have been shown to improve cognitive function. Additionally, exercise can change the composition and function of the gut microbiome, which may lead to improved cognitive function. Unfortunately, only about 50% of AYAs with cancer receive exercise information or meet the physical activity recommendations. Tailoring a virtually delivered exercise intervention to meet the unique needs of AYAs may improve access to exercise. Participating in the virtual home-based exercise intervention, RISE, may improve physical activity and cognitive impairment in AYA brain tumor survivors and may also help researchers understand the relationship of exercise on the gut microbiome and cognitive function.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of conducting a two-site pilot randomized controlled trial (RCT) to test the RISE in AYA brain tumor survivors.
II. Examine the impact of RISE on CRCI (primary) and physical activity (secondary).
EXPLORATORY OBJECTIVE:
I. Explore the impact of RISE on the gut microbiome diversity and composition.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (RISE INTERVENTION): Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.
ARM II (ATTENTION CONTROL): Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.
After completion of study intervention, patients are followed up at week 18.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jinbing Bai, PhD, RN
- Telefoonnummer: 404-727-2466
- E-mail: jinbing.bai@emory.edu
Studie Locaties
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital
-
Contact:
- Emily Bush, BS
- E-mail: emily.bush@emoryhealthcare.org
-
Hoofdonderzoeker:
- Jinbing Bai, PhD, RN
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- MD Anderson Cancer Center
-
Contact:
- Keri Schadler, PhD
- Telefoonnummer: 713-794-1035
- E-mail: klschadl@mdanderson.org
-
Contact:
- Maria Chang Swartz
- E-mail: mchang1@mdanderson.org
-
Hoofdonderzoeker:
- Keri Schadler, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 15-39 years
- With primary brain tumor with cranial radiotherapy
- 6 months to 4 years post cranial radiotherapy
- Functional Assessment of Cancer Therapy (FACT)-Cognitive Function score < 60 based on self-report (used among AYAs with non-neural cancer)
- Able to provide informed consent/assent
- Able to walk and receive clearance from a provider to participate based on the Physical Activity Readiness Questionnaire
- Currently engaging in < 150 minutes of physical activity per week
- Willing to use smartphone-based applications (app)
Exclusion Criteria:
- Secondary malignancies, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain
- Moderate to severe traumatic brain injury with brain damage beyond that expected from brain tumor and treatment
- Developmental disorders (e.g., autism) or major psychotic illness (e.g., schizophrenia, depression) to avoid confounding impact related to these disorders
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm I (RISE)
Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12. |
Ancillary studies Participate in personalized, progressive aerobic training
Andere namen:
Receive active lifestyle behavior coaching
Andere namen:
Receive access to Physitrack Participating in strength training exercises
Andere namen:
|
|
Actieve vergelijker: Arm II (attention control)
Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12. |
Ancillary studies Receive calls from the trainer
Andere namen:
Wear a Fitbit monitor |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Enrollment
Tijdsspanne: Up to 1.5 years
|
Feasibility will be ≥ 50% enrollment of eligible survivors. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 1.5 years
|
|
Adherence to research intervention of virtually supervised exercise program (RISE)
Tijdsspanne: Up to 12 weeks
|
Feasibility will be ≥ 75% adherence to RISE. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 12 weeks
|
|
Retention
Tijdsspanne: Up to 12 weeks
|
Feasibility will be ≥ 80% retention at end of intervention. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 12 weeks
|
|
Acceptability
Tijdsspanne: Up to 18 weeks
|
Will use an 11-item acceptability questionnaire. A ≥ 4 ("agree" to "strongly agree") per item equates to acceptability. Descriptive statistics (e.g., frequency and percentage) will be used. |
Up to 18 weeks
|
|
Change in physical activity levels
Tijdsspanne: Baseline up to 18 weeks
|
Will be measured by Fitbit. Physical activity estimates considered as valid if the monitor is worn ≥ 10 hours/day on ≥ 4 days. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Baseline up to 18 weeks
|
|
Change in cancer-related cognitive impairment
Tijdsspanne: Baseline up to 18 weeks
|
Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Baseline up to 18 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gut microbiome
Tijdsspanne: Up to 18 weeks
|
Fecal specimens will be collected for the gut microbiome. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
Up to 18 weeks
|
|
Physical function
Tijdsspanne: At baseline and at 12 and 18 weeks
|
Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
At baseline and at 12 and 18 weeks
|
|
Patient Quality of Life
Tijdsspanne: At baseline and at 12 and 18 weeks
|
Will be assessed by Patient Reported Outcomes Measurement Information System-29 recommended. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing. |
At baseline and at 12 and 18 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Jinbing Bai, PhD, RN, Emory University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neoplasmata per site
- Neoplasmata
- Neoplasmata van het zenuwstelsel
- Neoplasmata van het centrale zenuwstelsel
- Hersenneoplasmata
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Motorische activiteit
- Beweging
- Musculoskeletale fysiologische fenomenen
- Musculoskeletale en neurale fysiologische fenomenen
- Onderzoekstechnieken
- Epidemiologische methoden
- Therapeutica
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Volksgezondheid
- Milieu en volksgezondheid
- Modaliteiten fysiotherapie
- Patiëntenzorg
- Psychotherapie
- Gedragsdisciplines en activiteiten
- Transporttherapie
- Revalidatie
- Nazorg
- Continuïteit van patiëntenzorg
- Fysieke conditionering, mens
- Immunologische technieken
- Genetische technieken
- Epidemiologische studies
- Epidemiologische studie -kenmerken
- Chromatine -immunoprecipitatie
- High-throughput nucleotide sequencing
- Sequentie -analyse
- Sequentie -analyse, DNA
- Immunoprecipitatie
- Cohortstudies
- Oefening
- Weerstandstraining
- Gedragstherapie
- Chromatine immunoprecipitatie sequencing
- Vervolgstudies
Andere studie-ID-nummers
- STUDY00008229
- P30CA138292 (Subsidie/contract van de Amerikaanse NIH)
- STUDY00008229 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
- NCI-2025-00181 (Register-ID: CTRP (Clinical Trial Reporting Program))
- WINSHIP6364-24 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .